New research . . . suggests that a new kind of gene therapy can improve vision in people who have lost nearly all sight to RP.

Patients with XLRP treated with AGTC-501 gene therapy experienced improvements in visual function including retinal sensitivity . . .

Endogenous regenerative technology involves the use of a patient's biologically active proteins, growth factors and biomaterial scaffolds.

June 17, 2022 | Université de Genève Journal Reference Olivier Mercey, Corinne Kostic, Eloïse Bertiaux, Alexia Giroud, Yashar Sadian,...

UC Berkeley researchers have found that a drug once widely used to wean alcoholics off drinking may help improve sight in mice with RD.

Existing treatments only help a fraction of the estimated 100,000 Americans with this condition. But advances in gene therapy may soon help.

The FDA has granted orphan drug designation for chemically induced photoreceptor-like cells to treat retinitis pigmentosa.

FDA granted 4th Orphan Drug Designation for novel gene therapy product candidate (OCU400, Ocugen Inc.) in treatment of PDE6B gene mutation.

Our goal is to identify the onset of degeneration and devise gene-based therapies to ameliorate or cure the retina disease.

In 1972, Friedman and Roblin proposed that it was theoretically possible to introduce “good” DNA to replace defective DNA.

In 2017, the FDA approved a gene therapy for RP caused by RPE65. The decision marked the first approved treatment for any form RP.

Medical Hypothesis, Discovery Innovation Ophthalmology Journal | Harvey Siy Uy, MD, Pik Sha Chan, MD, and Franz Marie Cruz, MD | 2013...

Fierce Biotech | May 16, 2011, 08:05 am | Boston | PRNewswire-US Newswire Scientists from Schepens Eye Research Institute are the first...

Discusses stem cells, dev stages of the eye field, eye field transcriptional factors, and endogenous and exogenous sources of stem cells.